Literature DB >> 8186199

CD70 represents the human ligand for CD27.

R Q Hintzen1, S M Lens, G Koopman, S T Pals, H Spits, R A van Lier.   

Abstract

The recently identified CD27 ligand (L) is a type II transmembrane molecule with significant structural homology to tumor necrosis factor (TNF)-alpha, TNF-beta, lymphotoxin beta, CD40L, and CD30L. Using a CD27L specific mAb we examined the tissue distribution of the molecule, and found its expression to be restricted to B cells in occasional germinal centers, stromal cells in the thymic medulla, and scattered T cells in tonsils, skin and gut. As the limited expression of CD27L closely resembled the reported distribution of the activation antigen CD70, we tested whether CD70 represents the human CD27L. CD70 mAb were found to react with CD27L-expressing transfected mouse fibroblasts. Moreover a number of CD70 mAb could specifically interfere with the cellular binding of CD27L mAb. Thus, CD70 is identical to the human CD27L.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8186199     DOI: 10.1093/intimm/6.3.477

Source DB:  PubMed          Journal:  Int Immunol        ISSN: 0953-8178            Impact factor:   4.823


  30 in total

Review 1.  Epstein-Barr virus infection in the pathogenesis of nasopharyngeal carcinoma.

Authors:  G Niedobitek
Journal:  Mol Pathol       Date:  2000-10

Review 2.  Pancreatic ductal adenocarcinoma: a review of immunologic aspects.

Authors:  Megan B Wachsmann; Laurentiu M Pop; Ellen S Vitetta
Journal:  J Investig Med       Date:  2012-04       Impact factor: 2.895

3.  CD70 expression patterns in renal cell carcinoma.

Authors:  Lucia B Jilaveanu; Joshua Sznol; Saadia A Aziz; Dylan Duchen; Harriet M Kluger; Robert L Camp
Journal:  Hum Pathol       Date:  2012-03-07       Impact factor: 3.466

4.  CD70 Activation Decreases Pulmonary Fibroblast Production of Extracellular Matrix Proteins.

Authors:  Thi K Tran-Nguyen; Jianmin Xue; Carol Feghali-Bostwick; Frank C Sciurba; Daniel J Kass; Steven R Duncan
Journal:  Am J Respir Cell Mol Biol       Date:  2020-08       Impact factor: 6.914

5.  Antigen-presenting cell-derived signals determine expression levels of CD70 on primed T cells.

Authors:  S M Lens; P A Baars; B Hooibrink; M H van Oers; R A van Lier
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

6.  Effects of CD70 and CD11a in immune thrombocytopenia patients.

Authors:  Li Ma; Zeping Zhou; Hairong Jia; Hu Zhou; Aiping Qi; Huiyuan Li; Hongmei Wang; Lei Zhang; Renchi Yang
Journal:  J Clin Immunol       Date:  2011-05-04       Impact factor: 8.317

7.  Distinct cytokine-driven responses of activated blood gammadelta T cells: insights into unconventional T cell pleiotropy.

Authors:  David Vermijlen; Peter Ellis; Cordelia Langford; Anne Klein; Rosel Engel; Katharina Willimann; Hassan Jomaa; Adrian C Hayday; Matthias Eberl
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

8.  Targeting pancreatic and ovarian carcinomas using the auristatin-based anti-CD70 antibody-drug conjugate SGN-75.

Authors:  M C Ryan; H Kostner; K A Gordon; S Duniho; M K Sutherland; C Yu; K M Kim; A Nesterova; M Anderson; J A McEarchern; C-L Law; L M Smith
Journal:  Br J Cancer       Date:  2010-07-27       Impact factor: 7.640

9.  Soluble CD27-pool in humans may contribute to T cell activation and tumor immunity.

Authors:  Jianping Huang; Caroline Jochems; Austin M Anderson; Tara Talaie; Alessandra Jales; Ravi A Madan; James W Hodge; Kwong Y Tsang; David J Liewehr; Seth M Steinberg; James L Gulley; Jeffrey Schlom
Journal:  J Immunol       Date:  2013-05-15       Impact factor: 5.422

10.  Discriminatory Power of Combinatorial Antigen Recognition in Cancer T Cell Therapies.

Authors:  Ruth Dannenfelser; Gregory M Allen; Benjamin VanderSluis; Ashley K Koegel; Sarah Levinson; Sierra R Stark; Vicky Yao; Alicja Tadych; Olga G Troyanskaya; Wendell A Lim
Journal:  Cell Syst       Date:  2020-09-10       Impact factor: 10.304

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.